Here we report that BLT1 and BLT2 are expressed at low levels in an apparently silent state in human umbilical vein endothelial cells (HUVEC). However, treatment with LPS leads to a >10 fold increase in the levels of BLT1 mRNA without any significant effects on BLT2 mRNA. In parallel, LPS also increases the amounts of BLT1 protein.
T he leukotrienes (LTs) are a family of lipid mediators that play important roles in a variety of allergic and inflammatory reactions (1, 2) . These molecules are divided into two classes, the spasmogenic cysteinyl-LTs (cys-LT) and LTB 4 , which is a classical nM chemotactic agent produced by neutrophils, macrophages, and mast cells. Thus, LTB 4 is a potent chemoattractant for polymorphonuclear leukocytes, comparable to complement peptide C5a and fMet-Leu-Phe (3, 4) . Recent data also indicate that LTB 4 is a strong chemoattractant for T cells, creating a functional link between early innate and late adaptive immune responses (5) (6) (7) . Because of these biological effects, LTB 4 is regarded as an important chemical mediator in a variety of acute and chronic inflammatory diseases and only recently, genetic and biochemical evidence strongly implicate LTB 4 as a mediator of vascular inflammation and arteriosclerosis (8) (9) (10) . LTB 4 , is synthesized from arachidonic acid via the concerted action of 5-lipoxygenase, assisted by 5-lipoxygenase-activating protein and the terminal LTA 4 hydrolase (11) , usually in a single cell or via transcellular routes; this mechanism has been shown to occur in vivo (12, 13) .
LTB 4 signals primarily via a specific, high-affinity, G proteincoupled seven-transmembrane receptor, termed BLT 1 (14) . The BLT 1 gene is located on the human chromosome 14q11.2-q12 and SP1 binding to CpG regions appears to be important for basal transcription (15) . In the promoter region of the BLT 1 gene, an ORF encoding a highly homologous GPCR was found, which was subsequently identified as the second, low-affinity, receptor for LTB 4 and termed BLT 2 (16) . BLT 1 and BLT 2 signal through three classes of G proteins, namely G i , G q -like, and G z , and display different ligand affinity and specificity for LTB 4 and structurally related molecules (16, 17) . Northern blot analyses revealed BLT 1 mRNA expression almost exclusively in leukocytes (14) , activated macrophages (18) , and eosinophils (19) , whereas BLT 2 has a different expression profile with mRNA present in spleen, liver, ovary, and leukocytes. In addition, low levels of BLT 2 mRNA are also present in almost all human tissues (16) .
Endothelial cells are strategically located at the interface between the blood and parenchymal cells and take active part in many physiological and pathological processes, including inflammation. LTB 4 is very active in the microcirculation and promotes adhesion of leukocytes to the endothelium, followed by diapedesis and migration into surrounding tissues. Although it has been reported that LTB 4 can induce CD54 (or ICAM-1) expression in endothelial cells (20, 21) , the prevailing notion is that adhesive and migratory effects of LTB 4 primarily originate from its action on the leukocyte, where chemoattractants induce up-regulation of cell-adhesion molecules that can interact with their cognate receptors on endothelial cells (22, 23) .
Here, we report that LPS, TNF-␣, IL-1␤, and LTB 4 itself, differentially increase the expression of BLT 1 and͞or BLT 2 on HUVEC, which in turn allows LTB 4 mediated Ca 2ϩ signaling. We also show that LTB 4 can increase the release of monocyte chemoattractant protein-1 (MCP-1) and generation of nitrite (presumably from NO) from these cells. Taken together, our results indicate that endothelial cells are directly involved in the vascular response to LTB 4 -dependent inflammatory processes and calls for a reappraisal of the signal transduction mechanisms of the hyperadhesiveness for neutrophils induced by this lipid mediator.
Results
Human umbilical vein endothelial cells (HUVEC), cultured as described in Methods, express both BLT 1 and BLT 2 mRNA as well as BLT 1 receptor protein (BLT 2 receptor protein not analyzed), although their signaling capacity appear to be low or absent (see below).
Effects of LPS on the Expression of BLT Receptors. Treatment of HUVEC with LPS (100 ng͞ml) led to a rapid (within 60 min) increase in the levels of BLT 1 mRNA to amounts that were Ϸ12 times (11.8 Ϯ 1.3, n ϭ 4) above baseline (Fig. 1 ). This increase persisted at the same level after 120 min of incubation (11.6 Ϯ 1.8, n ϭ 4). In contrast, LPS did not have any significant impact on the BLT 2 mRNA levels, which were 1.4 Ϯ 0.3 and 1.8 Ϯ 0.3 times basal values after 60 and 120 min, respectively. Western blot analysis detected an immunoreactive band migrating as a protein with a molecular mass of Ϸ38 kDa, which is in good agreement with the calculated molecular mass of 37.6 kDa for BLT 1 (Fig. 1) . The specificity of the immunoreactivity was verified by using antisera preadsorbed with BLT 1 blocking peptide, which failed to detect the BLT 1 protein (data not shown). The amounts of immunoreactive protein corresponded well to the increase in mRNA. Thus, it increased significantly after 1 h of LPS treatment and remained elevated during at least 6 h (Fig. 1) . In a series of separate Western blots, the amounts of immunoreactive BLT 1 protein increased 2.8 Ϯ 0.6 times (n ϭ 5) relative to the untreated control. Treatment of HUVEC with 100 ng͞ml TNF-␣ led to a rapid increase in the amounts of BLT 2 mRNA, which were 4.9 Ϯ 1.3 times the control after 30 min and increased further to 6.2 Ϯ 0.8 times after 1 h. Thereafter, the effect leveled off, and after 120 min, BLT 2 mRNA was Ϸ6 times (6.4 Ϯ 1.3) above the levels in untreated cells (Fig. 2) . Treatment with TNF-␣ also led to a weak increase in BLT 1 mRNA, which peaked after 60 min (2.1 Ϯ 0.7 times). This slight increase in mRNA did not lead to a significant increase in the amounts of immunoreactive BLT 1 protein as assessed by Western blot (1.0 Ϯ 0.2 times, n ϭ 5). On the other hand, treatment of HUVEC with 5 units͞ml IL-1␤ increased the levels of both BLT 1 and BLT 2 receptor mRNA in a variable fashion, both with respect to degree of increase and time course. Thus, over a large series of experiments (n ϭ 10), treatment with IL-1␤ increased mRNA levels of BLT 1 and BLT 2 Ϸ2.5-7 and 4-12 times, respectively (data not shown). The mRNA levels peaked after Ϸ10-60 min, but very early responses were also observed (within minutes) in some experiments. In Western blot analysis, the levels of immunoreactive BLT 1 protein were either unaltered or increased significantly after 60 and 120 min (data not shown).
Effects of Ligand Binding on the Expression of BLT Receptors.
The natural ligand LTB 4 also induced BLT 1 , but not BLT 2 , mRNA and protein expression in a time-dependent manner. After stimulation of HUVEC with 100 nM LTB 4 , BLT 1 mRNA increased rapidly and stayed elevated for at least 2 h (Fig. 3) . Thus, after 30 min of incubation, the levels of BLT 1 mRNA had increased by 3.15 Ϯ 0.7 times (n ϭ 5) and then gradually diminished to 2.9 Ϯ 0.8 and 2.1 Ϯ 0.3 times the control levels, after 60 and 120 min, respectively. In contrast, the amounts of BLT 2 mRNA gradually decreased to levels corresponding to 0.4 Ϯ 0.2, 0.55 Ϯ 0.15, and 0.2 Ϯ 0.1 (n ϭ 3) times the control values, after 30, 60, and 120 min, respectively. The effects of LTB 4 on BLT 1 mRNA expression appeared specific, because LTC 4 , LTD 4 , and 5(S)-hydroxy-8,11,14-cis-6-trans-eicosatetraenoic acid (5-HETE) were without significant effects (data not shown). In addition, Western blot was performed on 2 ϫ 10 5 cells from HUVEC cultures stimulated with 100 nM LTB 4 (0, 1, 3, and 6 h). As observed after LPS stimulation, BLT 1 immunoreactivity increased significantly, particularly after 3 and 6 h (Fig. 3) .
Assessment of BLT Receptor Signaling. When quiescent HUVEC were stimulated with LTB 4 (100 nM) we observed no or minimal cytosolic calcium ([Ca 2ϩ ] i ) changes, the mean rise above the basal level was 26 Ϯ 9 nM (Fig. 4) , which is in line with a previous report (21) . However, when HUVEC had been exposed to LPS, IL-1␤, or TNF-␣ for 2-4 h, clear increases of [Ca 2ϩ ] i were seen, where 3 h of incubation conferred maximal responses; therefore, all experiments were performed with 3 h of LPS or cytokine treatment. At this time point, LPS treatment (100 ng͞ml) augmented the LTB 4 -induced [Ca 2ϩ ] i response 6.7-fold, or with 175 Ϯ 28 nM (n ϭ 20) above basal levels, where the onset of the response was gradual, reached a plateau after Ϸ1 min, and then slowly declined (Fig. 4 Upper). In contrast, when LPS was substituted by TNF-␣ (100 ng͞ml) LTB 4 induced a rapid and 4.3-fold enhanced [Ca 2ϩ ] i response (112 Ϯ 24 nM; n ϭ 9), peaking within 15-20 s and then declining to basal levels after 1-1.5 min (Fig. 4 Lower). Likewise, a 3 h IL-1␤ exposure caused a 4.6-fold rise of the LTB 4 response to 120 Ϯ 24 nM, with kinetics similar to TNF-␣ (n ϭ 6; data not shown). These responses of HUVEC to LTB 4 differed kinetically from that induced by LTB 4 in quiescent neutrophils (Fig. 4 Inset). As a control for the specificity of the response, we substituted LTB 4 with thrombin as the stimulus for [Ca 2ϩ ] i transients, but saw no enhancement of the response by means of previous LPS treatment (data not shown). IFN-␥ exposure for 3 h was associated with no rise of [Ca 2ϩ ] i upon LTB 4 stimulation. The LTB 4 -induced Ca 2ϩ responses appearing after treatment with LPS or TNF-␣ were completely blocked by pretreatment with the BLT 1 inhibitor CP-105696 (1 M) for 20 min (data not shown; n ϭ 4). The weaker BLT 1 antagonist U75302 (1 M; 20 min) influenced the LTB 4 response marginally in LPS treated cells (87% of the control, i.e., 153 Ϯ 13 nM) and TNF-␣ treated cells. U75302 also acted as an agonist (300 nM) on TNF-␣ or LPS treated endothelial cells with small but sustained Ca 2ϩ responses: 53 Ϯ 19 (n ϭ 6) and 112 Ϯ 48 nM (n ϭ 6), respectively.
A BLT 2 antagonist, LY-255283 (1 M for 20 min before addition of LTB 4 ) had different effects on the LTB 4 response in LPS or TNF-␣ treated cells. In the former, only a small part of the response was inhibited (Fig. 5 Upper), but in the latter the response was blocked, indistinguishable from that in HBSS treated HUVEC (Fig. 5 Lower).
We also tested the effect of a preincubation with LTB 4 itself and exposed HUVEC to the ligand for 3-6 h. Upon a second stimulation with LTB 4 , enhanced [Ca 2ϩ ] i responses were observed (Fig. 6) . The maximum rise above basal levels, 217 Ϯ 35 nM (n ϭ 4), occurred at 4 h and declined to 55 nM after a 6-h exposure. The kinetics of the response was intermediated between LPS and TNF-␣, in that many cells reacted with a peak within 10 -20 s and responses then declined slowly, whereas other cells reacted more slowly, with a peak after Ϸ1 min (Fig. 6) . In a control experiment with a similar exposure to LY-255283, the endothelial cells did not respond to subsequent LTB 4 stimulation.
Effects of LTB4 on Nitrite Generation and MCP-1 Release from HUVEC.
In these experiments, we focused on other physiological effects of the up-regulation of BLT 1 by LPS or LTB 4 . To this end, we treated HUVEC for 3 h with either LPS (at 100 ng͞ml), LTB 4 (250 nM), or Hanks' balanced salt solution (HBSS) alone, then removed media and added new media and stimulus (i.e., LTB 4 ) or HBSS. Supernatants were removed after incubation for 15 min and assayed for nitrite or MCP-1. Controls (i.e., 100%) are samples treated with HBSS for 3 h and then exposed to HBSS alone for 15 min; they contained 2.3 Ϯ 0.4 M of nitrite and 656 Ϯ 221 pg͞ml of MCP-1 (n ϭ 18).
As shown in Fig. 7 Left, nitrite release (supposedly reflecting NO generation or non-nitric oxide synthase associated nitrite production) increased in HBSS-treated samples that were stimulated by LTB 4 for 15 min to 148%. In good agreement with the results of the Ca 2ϩ experiments described above, treatment with LPS for 3 h, followed by LTB 4 , caused a significant (P ϭ 0.04; n ϭ 10) up-regulation of nitrite release to 227%, which is a 2.4-fold increase compared to samples treated similarly with LPS but exposed to HBSS alone for the 15-min period. In this assay, the antagonist CP-105696 displayed an agonistic action hampering evaluation of the involvement of BLT 1 (n ϭ 6).
In similarly designed experiments on MCP-1 release (Fig. 7 Right), we found that LPS causes a strong MCP-1 release; thus, we used LTB 4 treatment for 3 h to up-regulate BLT 1 , as described above. Compared to controls first treated with HBSS alone and then with LTB 4 (which increased MCP-1 release 2.15-fold), samples treated with LTB 4 during both time periods showed 3.92-fold enhanced cytokine release (n ϭ 17; P ϭ 0.02), suggesting that priming with LTB 4 enhanced the subsequent LTB 4 response (Fig. 7) . When CP-105696 was present during the 3-h pretreatment period, most of the subsequent response to a second LTB 4 challenge was abolished. Discussion LTB 4 is a classical chemoattracting agent that also promotes neutrophil adhesion and diapedesis through the endothelial cell barrier, a key sequence of events during vascular inflammatory responses and host defense. However, the molecular mechanisms of LTB 4 -induced transendothelial migration of neutrophils is not fully understood, but seems to involve soluble factors as well as activation of both leukocyte and endothelial cell adhesion molecules (23) . Direct effects of LTB 4 on endothelial cells have also been discussed, although these cells have appeared only weakly, if at all, reactive to this mediator (24, 25) . In this study, we sought to identify factors that might turn on BLT receptor expression and function in these cells.
LPS and TNF-␣ Differentially Up-Regulate BLT Receptor Expression and
Render HUVEC Responsive to LTB4. LPS treatment of HUVEC led to a rapid increase in BLT 1 mRNA, which was also reflected in significantly enhanced levels of BLT 1 immunoreactive protein (Fig. 1) . Interestingly, from an almost insensitive state in quiescent cells, LPS treated cells responded with a robust increase in [Ca 2ϩ ] i upon stimulation with LTB 4 (Fig. 4) that could be blocked with CP-105696, a selective BLT 1 antagonist, but not with the BLT 2 -selective LY-255283. Moreover, the Ca 2ϩ response in HUVEC exhibited a different kinetic pattern as compared to that in human neutrophils, suggesting that other intracellular signaling pathways, or a different BLT 1 receptor complex, are involved.
TNF-␣ had an almost opposite effect on the expression of BLT receptors with a rapid increase in the levels of BLT 2 mRNA and only modest and partially reversible effects on BLT 1 mRNA amounts (Fig. 2) . As observed with LPS, treatment of HUVEC with TNF-␣ allowed LTB 4 induced Ca 2ϩ signaling (Fig. 4) , presumably via BLT 2 because TNF-␣ did not significantly increase BLT 1 protein and the LTB 4 signal could be blocked with LY-255283.
Considering the unusual gene structure of BLT 1 and BLT 2 , with the ORF of the BLT 2 gene located in the promoter of the BLT 1 gene (15), it is interesting that signaling via TNF-␣ or LPS can selectively increase mRNA levels of only one gene at a time. Further work will hopefully elucidate the molecular mechanisms involved. 6 . Ca 2ϩ responses elicited by LTB4 in LTB4-treated HUVEC. When HUVEC had been treated with LTB 4 for 4 h, followed by activation by LTB4, a major response that was 8.3-fold higher than that of HUVEC pretreated with HBSS alone was noted. When LTB 4 was substituted by LY-255283 (control) as pretreatment, no Ca 2ϩ response was observed. 
The Natural BLT Ligand LTB4 Increases the Expression of BLT1 in HUVEC.
Although LTB 4 does not evoke significant Ca 2ϩ transients in quiescent HUVEC, the ligand can still influence gene expression. Thus, incubations of HUVEC with LTB 4 led to significant increases in the levels of BLT 1 mRNA and protein (Fig. 3) . Pretreatment of HUVEC with LTB 4 also turned on their ability to signal with [Ca 2ϩ ] i transients in response to ligand activation, presumably via BLT 1 . Apparently, the expression and functional state of BLT 1 receptors in HUVEC seem to be regulated via a signaling pathway involving binding of the receptor's own primary ligand. It may be noted that modulation of BLT 1 expression by LTB 4 has been observed in human neutrophils, thus corroborating our results in HUVEC (26) .
LTB4 Promotes Nitrite͞NO Generation and MCP-1 Release From HUVEC.
In quiescent HUVEC, LTB 4 only elicits weak Ca 2ϩ responses, and not much is known regarding the functional consequences of signaling via BLT receptors. We reasoned that up-regulation of BLT receptors would perhaps uncover previously unknown functional responses of HUVEC to LTB 4 . However, LPS and cytokines are powerful activators of endothelial cells and gave maximal responses in almost all assays tested, e.g., expression of adhesion molecules and cytokine release. Nonetheless, we could show that LTB 4 promotes nitrate generation in HUVEC and that this effect is augmented after pretreatment with LPS, presumably reflecting a functional up-regulation of BLT 1 . We also found that LTB 4 can release MCP-1 from HUVEC, and this response is increased after pretreatment with the ligand. For this bioactivity, we could demonstrate that BLT 1 receptors are involved (Fig. 7) .
BLT Receptor Expression and Function on HUVEC May Be Modulated by the Profile of LPS and Cytokines.
Our results indicate that endothelial cells respond to LPS, TNF-␣, and IL-1␤ with increased expression of BLT receptors capable of transmitting LTB 4 signals and functional responses. Interestingly, each of these agents had different effects on the expression of the respective receptor subtype, BLT 1 and BLT 2 . Thus, depending on the relative abundance of these proinflammatory substances, the receptor composition and function will be tuned at the surface of endothelial cells. Challenge with LPS elicits an innate immune response that mimics bacterial infection and sepsis. Downstream in this pathway, cytokines will be released, including TNF-␣ and IL-1␤. Inasmuch as LTB 4 is regarded as an important signaling molecule in the innate immune system, the actions of LPS, TNF-␣, and IL-1␤ on the responsiveness of endothelial cells to this particular mediator appear adequate and functional.
Potential for LTB4-BLT Receptor Interactions During Leukocyte Adhesion. It has been shown that LTB 4 induces hyperadhesiveness of endothelial cells, an effect that appears to be mediated via increased activity of CD54 (20, 21) . One can then envisage a scenario in which activated leukocytes release LTB 4 that, in turn, acts on endothelial cells that are prepared to transmit the signals and further promote the adhesion and transmigration process. This concept is further supported by our findings that LTB 4 stimulation of HUVEC appears to promote generation of NO, a potent vasodilator that can increase blood flow, and increases the release of MCP-1, a powerful chemoattractant for monocytes and T cells (27) . MCP-1 could potentially signal back to the adhering leukocytes to further stimulate LTB 4 synthesis, as has been shown for macrophages in vitro (28) . Therefore, our data support the notion that LTB 4 can promote leukocyte adhesion, not only via effects on the leukocyte, but also via direct actions on the endothelium. These actions also include up-regulation of the BLT 1 receptor, which presumably will further amplify the functional effects of LTB 4 . It is also worth noting that endothelial cells contain LTA 4 hydrolase, thus allowing synthesis of LTB 4 via cell-cell interactions and transcellular biosynthesis.
Several lines of evidence indicate that LTs are involved in vascular inflammation, in particular arteriosclerosis (10) . Here, endothelial cells are important players in the pathogenesis and, interestingly, LTB 4 has been ascribed a specific role in the disease processes (9) . Our results provide clues to understanding the mechanisms of leukocyte adherence and transmigration of endothelial cells. Moreover, they may have implications for the molecular pathology of cardiovascular and rheumatic diseases and point to BLT receptors as potential targets for pharmacological intervention in chronic inflammatory disorders.
Methods
Materials. LTB 4 , 5(S)-hydroxy-8,11,14-cis-6-trans-eicosatetraenoic acid, LTC 4 , LTD 4 , and U75302 were purchased from Biomol (Plymouth Meeting, PA). Oligonucleotides were from Cybergene (Huddinge, Sweden). LPS from Escherichia coli serotype O55:B5, TNF-␣, IL-1␤, VCl 3 , sulfanilamide, N-(1-naphtyl)-ethylene diamine, H 3 PO 4, Fura 2-AM, and Pluronic F127 were from Sigma. Polyclonal antibodies against BLT 1 (and BLT 2 ) were purchased from Cayman Chemical (Ann Arbor, MI). LY-255283 and CP-105696 were kind gifts from Lilly Research Laboratories (Indianapolis, IN) and Pfizer, respectively.
Cell Culturing. HUVEC were obtained from the vessels by collagenase treatment, cultivated, and identified as described (21, 29) . HUVEC were trypsinized when confluent, resuspended in medium, and seeded into new culture flasks (for a maximum of two passages, once per week). The cell viability was Ͼ95%, as judged by cell morphology, trypan blue exclusion, and analysis of lactate dehydrogenase release. Glass dishes were seeded with 10 4 HUVEC per well and grown until confluence.
Analysis of mRNA by RT-PCR. Preparation of total RNA and RT-PCR were essentially as described (30) . Briefly, RT-PCR was conducted with a GeneAmp͞PerkinElmer RNA PCR kit, using 1 g of RNA for reverse transcription, followed by two rounds (30 ϩ 20 cycles) of DNA amplification with annealing between 50°C and 60°C and extension at 72°C, using a GeneAmp͞PerkinElmerPCR system 2400. The nested PCR primers used were: BLT 1 : first PCR, 5Ј-ATGAACACTACATCTTCT-GCAGC-3Ј, 5Ј-CTAGTTCAGTTCGTTTAACTTGAGAGG-3Ј; second PCR, 5Ј-AGGTGTAGAGTTCATCTCTCTGCT-3Ј, 5Ј-CTCCAGCAGCTTGGCGACGAAGC-3; BLT2: first PCR, 5Ј-CATTCTTGTCTTACCCTCTGC-3Ј, 5Ј-AGTTCGGAG-CTCCATGGTCC-3Ј; second PCR, 5Ј-GTGGTAGAGATAGT-GACAGC-3Ј, 5Ј-AAGGTTGACTGCGTGGTAGG-3Ј. For identification of the BLT 1 and BLT 2 mRNA, the corresponding DNA fragments generated by RT-PCR were sequenced by using the DYEnamic ET terminator cycle sequencing premix kit (Amersham Pharmacia). For semiquantitative analysis of PCR products, the fluorescent dye PicoGreen (Molecular Probes) was used as described (31, 32) . The fluorescence was measured ( ex ϭ 485 nm; em ϭ 538 nm) in a SpectraMax GeminiXS fluorometer from Molecular Devices. The standard curve for the quantitative analysis was obtained with DNA standard in TE buffer supplied by the manufacturer and was linear from 1 to 1,000 ng per well. The results were recalculated relative to the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase amplified from each sample and expressed as mean Ϯ SD.
Immunoblotting. Aliquots of 10 5 cells were mixed with loading buffer containing SDS, heated for 5 min to 95°C, and chilled on ice. Samples were then electrophoresed through an SDS͞ polyacrylamide gel (4-15% gradient gel; Bio-Rad) at 120 V for Ϸ70 min and subsequently electroblotted onto a poly(vinyl-difluoride) membrane (PALL, Fluorotrans Transfer membrane). The efficiency of the protein transfer was controlled by Coomassie staining of the gel. Membranes were then soaked for 2 h in 0.05% T-TBS [20 mM Tris⅐Cl, pH 7.5, with 0.5 M NaCl and 0.05% (vol͞vol) Tween 20] containing 5% (wt͞vol) nonfat dry milk. Blots were rinsed and washed twice for 5 min in 0.05% T-TBS and subsequently incubated for 14 h at 4°C with a BLT 1 polyclonal antiserum (dilution 1:1,000) in 0.05% T-TBS containing 2% dry milk. After incubation, blots were rinsed and washed twice for 10 min with 0.05% T-TBS followed by a 1-h incubation at 25°C with a donkey anti-rabbit IgG antibody coupled to horseradish peroxidase for detection of BLT 1 receptor. Detection of immunoreactive bands was carried out with the enhanced chemiluminescence detection method (ECL PLUS kit; Amersham Pharmacia Life Science) according to the manufacturer's instructions. Results were quantitated with a LAS-1000 Pro version 2.0 image analyzer with IMAGE GAUGE version 3.46 software (Fuji).
Calcium Mobilization Experiments. Mobilization of [Ca 2ϩ ] i was monitored spectrophotometrically by using Fura 2-AM, as described (33) . In one single microscopic field, the system generates individual data from 5 to 10 cells and calculates a mean value. The results are given as the ratio of fluorescence between 340 and 380 nm, calibrated and calculated with the MIRACAL (Life Science Resources, Cambridge, U.K.) software, according to the recommendations of the manufacturer.
MCP-1 Analyses. MCP-1 concentrations in supernatants of HUVEC, incubated in HBSS with 2% FCS with or without stimuli, were analyzed by ELISA according to the manufacturer's instructions (R & D Systems). Values were normalized to unstimulated controls set to 100%.
Assay of Nitrite. Formation of NO was analyzed by measurements of nitrite͞nitrate, based on a modified Griess reaction (34, 35) . In brief, HUVEC were stimulated for indicated time periods with HBSS or LTB 4 , and supernatants were harvested and centrifuged for 6 min at 1,850 ϫ g. The samples (100 l), together with nitrite͞nitrate standards, were mixed with 100 l of VCl 3 (8 mg͞ml) in 1 M HCl and nitrite and then quantified spectrophotometrically at 540 nm by using Griess reagent [0.5% (wt͞vol) sulfanilamide͞0.05% (wt͞vol) N-(1-naphtyl) 
